Easyway Biomedical and its subsidiary, Tulex Pharmaceuticals Inc., will collaborate with Handa Biotech and its subsidiary, Handa Neuroscience, LLC, to jointly develop TLX-050 for the treatment of neurological disorders. Easyway Biomedical and its subsidiary, Tulex Pharmaceuticals Inc., will be responsible for early-stage development and milestone revenue collection. Costs incurred during the development process and future profit sharing upon product launch will be shared and allocated according to the proportions specified in the contract between this company, its subsidiary Tulex Pharmaceuticals Inc., and Handa Biotech and its subsidiary, Handa Neuroscience, LLC.

According to the contract signed by both parties, specific milestone payments, cost sharing, and profit distribution ratios shall be kept confidential by both parties.